Umeclidinium bromide (trade name Incruse Ellipta) is a long-acting
muscarinic antagonist approved for the maintenance treatment of
chronic obstructive pulmonary disease (COPD).
It is also approved for this indication in combination with
vilanterol (as
umeclidinium bromide/vilanterol
Umeclidinium bromide/vilanterol, sold under the brand name Anoro Ellipta, among others, is a fixed-dose combination medication for the treatment of chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) is a type o ...
) and also as a triple-therapy combination as
fluticasone furoate/umeclidinium bromide/vilanterol
Fluticasone furoate/umeclidinium bromide/vilanterol, sold under the brand name Trelegy Ellipta among others, is a fixed-dose combination inhaled medication that is used for the maintenance treatment of chronic obstructive pulmonary disease (COPD ...
.
It is on the
World Health Organization's List of Essential Medicines.
In 2020, it was the 245th most commonly prescribed medication in the United States, with more than 1million prescriptions.
References
External links
*
*
Bromides
Drugs acting on the respiratory system
GSK plc brands
Muscarinic antagonists
Quaternary ammonium compounds
Quinuclidines
Bronchodilators
{{respiratory-system-drug-stub